Physician

Andrew L Ondo, M.D.

According to 2025 Medicare claims, Andrew Ondo, M.D. (NPI: 1275536559) practices dermatology in the Las Cruces, NM market, with the plurality of this provider's patient population coming from Dona Ana, NM. This provider's primary affiliated billing organization is DERMATOLOGY OF LAS CRUCES, PC (NPI: 1780075135; TIN: 47-2805475) and primary practice location at 88011-4620.

Ondo's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,685 traditional Medicare patients, billed 14,161 HCPCS/CPT codes, and received $406,752 in Medicare payments. The top billing code was 17110 (Destruction of skin growth, 1-14 growths). Part D data shows 1,438 prescription claims across 648 beneficiaries totaling $585,757 in drug costs, led by Cosentyx Sensoready (2 Pens) (Secukinumab). Open Payments data shows 3 records totaling $135. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $171,822 to $585,757. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$224K$448K2015 Medicare payment: $407,698 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $402,346 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $416,714 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $425,493 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $447,808 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $376,317 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $433,654 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $411,332 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $406,226 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $406,752 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
20151,72916,574$407,698
20161,79816,139$402,346
20171,86516,877$416,714
20181,93717,859$425,493
20191,82116,859$447,808
20201,66714,900$376,317
20211,76014,949$433,654
20221,79714,459$411,332
20231,78114,848$406,226
20241,68514,161$406,752

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$351K$702K2015 Drug cost: $171,822 (USD; Tot_Drug_Cst)2016 Drug cost: $143,422 (USD; Tot_Drug_Cst)2017 Drug cost: $164,001 (USD; Tot_Drug_Cst)2018 Drug cost: $185,950 (USD; Tot_Drug_Cst)2019 Drug cost: $217,552 (USD; Tot_Drug_Cst)2020 Drug cost: $326,149 (USD; Tot_Drug_Cst)2021 Drug cost: $497,499 (USD; Tot_Drug_Cst)2022 Drug cost: $621,159 (USD; Tot_Drug_Cst)2023 Drug cost: $702,182 (USD; Tot_Drug_Cst)2024 Drug cost: $585,757 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015441929$171,822
2016430902$143,422
2017494975$164,001
2018497971$185,950
20195601,036$217,552
2020507985$326,149
20215571,086$497,499
20225401,151$621,159
20235931,232$702,182
20246481,438$585,757

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
17110Destruction of skin growth, 1-14 growths510594$67
11102Biopsy of related skin growth, first growth312343$57
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more1,4081,841$57
17000Destruction of precancer skin growth, 1 growth1,1941,527$32
17003Destruction of precancer skin growth, 2-14 growths9637,853$5

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Cosentyx Sensoready (2 Pens)Secukinumab13364$93,388
Clobetasol PropionateClobetasol Propionate1303,927$7,526
AcitretinAcitretin19540$5,496
FluorouracilFluorouracil451,216$3,123
DutasterideDutasteride977,437$3,061

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.3$135Incyte Corporation
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Andrew L. Ondo, M.D.?

Tedicare shows public-source Medicare data for Andrew L. Ondo, M.D. (NPI 1275536559), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Andrew L. Ondo, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Andrew L. Ondo, M.D.?

Andrew L. Ondo, M.D. is linked to DERMATOLOGY OF LAS CRUCES, PC (billing NPI 1780075135) in the available physician profile data.

Does Andrew L. Ondo, M.D. have Open Payments data?

Andrew L. Ondo, M.D. has 3 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.